Alnylam Pharmaceuticals

Yahoo Finance • 2 days ago

Is Alnylam Pharmaceuticals (ALNY) an Undervalued Stock?

PGIM, an investment management company, released its “PGIM Jennison Health Sciences Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equities in the second quarter of 2025 experienced significant vola... Full story

Yahoo Finance • 2 days ago

Does Alnylam Pharmaceuticals (ALNY) Have the Potential to Generate Strong Long-Term Growth?

Parnassus Investments, an investment management company, released the “Parnassus Mid Cap Growth Fund” second quarter 2025 investor letter. A copy of the letter can be downloaded here. The Fund (Investor Shares) returned 13.29% (net of fees... Full story

Yahoo Finance • 5 days ago

Discover 3 Stocks That Might Be Trading Below Their Estimated Fair Value

As U.S. stock indexes reach new highs, with the S&P 500 and Nasdaq posting their third consecutive week of gains, investors are increasingly focused on identifying opportunities that might be trading below their estimated fair value. In th... Full story

Yahoo Finance • 6 days ago

Jefferies sees broad equity opportunities beyond tech leaders

[Wall Street in New York City] JaysonPhotography/iStock via Getty Images With the S&P 500 (SP500 [https://seekingalpha.com/symbol/SP500]) up 13% year-to-date but gains concentrated in a narrow group of large-cap technology names, Jefferie... Full story

Yahoo Finance • 9 days ago

Alnylam Pharmaceuticals Insiders Sold US$12m Of Shares Suggesting Hesitancy

Many Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) insiders ditched their stock over the past year, which may be of interest to the company's shareholders. When evaluating insider transactions, knowing whether insiders are buying is usually... Full story

Yahoo Finance • 11 days ago

Validea Detailed Fundamental Analysis - ALNY

Below is Validea's guru fundamental report for ALNYLAM PHARMACEUTICALS, INC. (ALNY). Of the 22 guru strategies we follow, ALNY rates highest using our Twin Momentum Investor model based on the published strategy of Dashan Huang. This mome... Full story

Yahoo Finance • 14 days ago

Will Positive HELIOS-B Data and $575 Million Offering Transform Alnylam’s (ALNY) RNAi Therapy Narrative?

In early September 2025, Alnylam Pharmaceuticals announced and completed a US$575 million convertible zero coupon senior unsecured note offering due September 2028 and presented extensive long-term data from the HELIOS-B Phase 3 study of A... Full story

Yahoo Finance • 15 days ago

Guru Fundamental Report for ALNY

Below is Validea's guru fundamental report for ALNYLAM PHARMACEUTICALS, INC. (ALNY). Of the 22 guru strategies we follow, ALNY rates highest using our Twin Momentum Investor model based on the published strategy of Dashan Huang. This mome... Full story

Yahoo Finance • 16 days ago

Top 20 biopharma market caps fall 5.7% amid industry challenges

The biopharmaceutical industry faces headwinds from the Trump administration’s ongoing tariffs and drug pricing pressures in the US. As a result, the top 20 global biopharmaceutical companies have reported a downturn of 5.7% in their combi... Full story

Yahoo Finance • 17 days ago

Alnylam prices $575M convertible senior notes

* Alnylam Pharmaceuticals (NASDAQ:ALNY [https://seekingalpha.com/symbol/ALNY]) priced [https://seekingalpha.com/pr/20227268-alnylam-announces-pricing-of-upsized-offering-of-575-million-convertible-senior-notes] its previously announced p... Full story

Yahoo Finance • 18 days ago

Alnylam announces proposed offering of $500M convertible senior notes

* Alnylam Pharmaceuticals (NASDAQ:ALNY [https://seekingalpha.com/symbol/ALNY]) has commenced a private offering of $500 million aggregate principal amount of convertible senior notes due 2028. * The notes will be senior, unsecured obli... Full story

Yahoo Finance • 23 days ago

RNAi Technology Market Size to Reach USD 6.63 Billion with 10.4% CAGR by 2033, Report by DataM Intelligence

AUSTIN, Texas and TOKYO, Sept. 4, 2025 /PRNewswire/ -- According to DataM Intelligence, the RNAi technology market size reached US$ 2.75 Billion in 2024 from US$ 2.51 Billion in 2023 and is expected to reach US$ 6.63 Billion by 2033, growi... Full story

Yahoo Finance • 25 days ago

Should You Add Alnylam Pharmaceuticals (ALNY) to Your Portfolio?

ClearBridge Investments, an investment management company, released its “ClearBridge All Cap Growth Strategy” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the second quarter, growth stocks led the st... Full story

Yahoo Finance • 27 days ago

Large-cap biotech is a sector to watch for investors: Analysts

Wall Street is looking for new ways to park cash in healthcare names, and large-cap biotechs have begun to gain steam. This asset class differs from traditional large-cap pharmaceutical companies — typically with a $200 billion market cap... Full story

Yahoo Finance • 28 days ago

Alnylam to advance Roche-partnered heart drug to late-stage trial despite mid-stage setback

[Alnylam Pharmaceuticals, Inc.] hapabapa Alnylam Pharmaceuticals (NASDAQ:ALNY [https://seekingalpha.com/symbol/ALNY]) announced on Saturday that the company and its partner Roche (OTCQX:RHHBY [https://seekingalpha.com/symbol/RHHBY]) would... Full story

Yahoo Finance • 28 days ago

Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension

Phase III trial informed by comprehensive KARDIA data set generated through three Phase II studies: KARDIA-1, KARDIA-2 and KARDIA-3In the Phase II KARDIA-3 study, presented today as a late breaker at the European Society of Cardiology Cong... Full story

Yahoo Finance • 28 days ago

Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension

–  Phase III trial informed by comprehensive KARDIA data set generated through three Phase II studies: KARDIA-1, KARDIA-2 and KARDIA-3 – –  In the Phase II KARDIA-3 study, presented today as a late breaker at the European Society of Cardi... Full story

Yahoo Finance • last month

Alnylam to Webcast Presentations at Upcoming September Investor Conferences

CAMBRIDGE, Mass., August 27, 2025--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conf... Full story

Yahoo Finance • last month

Scenic Enters License and Research Agreement with Alnylam

Amsterdam, the Netherlands, August 26, 2025 – Scenic Biotech, a pioneer in modifier therapies for severe diseases, today announced a license and research agreement with Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) to leverage Scenic's Cell... Full story

Yahoo Finance • last month

ALNY Quantitative Stock Analysis

Below is Validea's guru fundamental report for ALNYLAM PHARMACEUTICALS, INC. (ALNY). Of the 22 guru strategies we follow, ALNY rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This grow... Full story